PMC:7795856 / 3267-3457 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"129","span":{"begin":73,"end":76},"obj":"Species"},{"id":"130","span":{"begin":100,"end":103},"obj":"Species"},{"id":"133","span":{"begin":52,"end":71},"obj":"Disease"},{"id":"134","span":{"begin":79,"end":98},"obj":"Disease"}],"attributes":[{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"Tax:10407"},{"id":"A130","pred":"tao:has_database_id","subj":"130","obj":"Tax:11103"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"MESH:D019694"},{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"MESH:D019698"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"adaxin™ is clinically approved for the treatment of chronic hepatitis B (HBV), chronic hepatitis C (HCV), as a vaccine adjuvant, and as adjuvant therapy for chemotherapy-induced immune suppr"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":52,"end":69},"obj":"Phenotype"},{"id":"T8","span":{"begin":79,"end":96},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0200123"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0200123"}],"text":"adaxin™ is clinically approved for the treatment of chronic hepatitis B (HBV), chronic hepatitis C (HCV), as a vaccine adjuvant, and as adjuvant therapy for chemotherapy-induced immune suppr"}